CNS Drugs

, Volume 15, Issue 10, pp 797–817 | Cite as

Role of Estrogen in the Aetiology and Treatment of Mood Disorders

Review Article

Abstract

Worldwide, the prevalence of depression in women is significantly greater than in men. Available data suggest that estrogen, or its absence, is strongly implicated in the regulation of mood and behaviour, as well as in the pathobiology of mood disorders.

The multiple effects of estrogens and their complex interactions with the CNS and endocrine system have been well documented, although the specific, multifaceted role of estrogen in each dysphoric state has yet to be elucidated. Several facts suggest that estrogen plays a vital role in the precipitation and course of mood disorders in women. Gender differences in the prevalence of depression first appear after menarche, continue through reproductive age, and dissipate after perimenopause. Periods of hormonal fluctuations or estrogen instability (i.e. premenstrually, postpartum, perimenopausally) have been associated with increased vulnerability to depression among susceptible women. It is plausible that the phenotype of these depressions is distinguishable from those that are not associated with reproductive events or that occur in men.

Based on current knowledge, estrogen treatment for affective disorders may be efficacious in two situations: (i) to stabilise and restore disrupted homeostasis — as occurs in premenstrual, postpartum or perimenopausal conditions; and (ii) to act as a psychomodulator during periods of decreased estrogen levels and increased vulnerability to dysphoric mood, as occurs in postmenopausal women. There is growing evidence suggesting that estrogen may be efficacious as a sole antidepressant for depressed perimenopausal women. It is still unclear whether estrogen is efficacious as an adjunct to selective serotonin reuptake inhibitors or as one of the paradigms to manage treatment-resistance depression in menopausal women, but such efficacy is plausible.

References

  1. 1.
    Kessler R. Gender and mood disorders. In: Goldman MB, Hatch MC, editors. Women and health. San Diego (CA): AcademicPress, 2000: 989–96Google Scholar
  2. 2.
    Weissman MM, Bland RC, Canino GJ, et al. Cross-nationalepidemiology of major depression and bipolar disorder. JAMA 1996; 276(4): 293–9PubMedCrossRefGoogle Scholar
  3. 3.
    Weissman MM, Livingston BM, Leaf PJ. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America. New York: Free Press, 1991Google Scholar
  4. 4.
    Van Valkingburg C, Akiskal HS, Puzantian V, et al. Anxious depression: clinical, family history, and naturalistic outcome — comparisons with panic and major depressive disorders. J Affect Disord 1984; 6: 67–82CrossRefGoogle Scholar
  5. 5.
    Parry BL. Reproductive factors affecting the course of affectiveillness in women. Psychiatr Clin North Am 1989; 12(1): 207–20PubMedGoogle Scholar
  6. 6.
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-monthprevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8–19PubMedCrossRefGoogle Scholar
  7. 7.
    Kornstein SG, Schatzberg AF, Yonkers KA, et al. Gender differences in presentation of chronic major depression. Psychopharmacol Bull 1995; 31: 711–8PubMedGoogle Scholar
  8. 8.
    Kendler KS, Eaves LJ, Walters EE, et al. The identification andvalidation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996; 53(5): 391–9PubMedCrossRefGoogle Scholar
  9. 9.
    Stunkard AJ, Fernstrom MH, Price A, et al. Direction of weightchange in recurrent depression: consistency across episodes.Arch Gen Psychiatry 1990; 47: 857–60PubMedCrossRefGoogle Scholar
  10. 10.
    West ED, Dally PJ. Effect of iproniazid in depressive syndromes.BMJ 1959; 1: 1491-4PubMedCrossRefGoogle Scholar
  11. 11.
    Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 1993; 23(2): 157–62PubMedCrossRefGoogle Scholar
  12. 12.
    Halbreich U, Endicott J, Schacht S, et al. The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form. Acta Psychiatr Scand 1982; 65(1): 46–65PubMedCrossRefGoogle Scholar
  13. 13.
    Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18(5): 390–8PubMedCrossRefGoogle Scholar
  14. 14.
    Halbreich U. Premenstrual syndromes. In: Halbreich U, editor. Ballière’s clinical psychiatry: international practice and research. London: Ballière Tindall, 1996: 667–86Google Scholar
  15. 15.
    Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 1997; 95(3): 169–76PubMedCrossRefGoogle Scholar
  16. 16.
    Appleby L, Gregoire A, Platz C. Screening women for high risk postnatal depression. J Psychosom Res 1994; 38: 539–45PubMedCrossRefGoogle Scholar
  17. 17.
    Kumar R, Robson KM. Aprospective study of emotional disorders in childbearing women. Br J Psychiatry 1984; 144: 35–47PubMedCrossRefGoogle Scholar
  18. 18.
    O’Hara MW, Swain AM. Rates and risk of postpartum depression — a meta-analysis. Int Rev Psychiatry 1996; 8: 37–54CrossRefGoogle Scholar
  19. 19.
    Halbreich U. Role of estrogen in postmenopausal depression.Neurology 1997; 48(5 Suppl. 7): S16–9PubMedCrossRefGoogle Scholar
  20. 20.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  21. 21.
    Halbreich U, Endicott J. Relationship of dysphoric premenstrualchanges to depressive disorders. Acta Psychiatr Scand 1985; 71(4): 331–8PubMedCrossRefGoogle Scholar
  22. 22.
    Yonkers KA. The association between premenstrual dysphoricdisorder and other mood disorders. J Clin Psychiatry 1997;58 Suppl. 15: 19–25Google Scholar
  23. 23.
    Coppen A. The prevalence of menstrual disorders in psychiatricpatients. Br J Psychiatry 1965; 111: 155–67PubMedCrossRefGoogle Scholar
  24. 24.
    Kashiwagi T, McClure JN, Wetzel R. Premenstrual affectivesyndrome and psychiatric disorder. Dis Nerv Syst 1976; 37:116–9PubMedGoogle Scholar
  25. 25.
    Schuckit MA, Daly V, Herrman G, et al. Premenopausal symptomsand depression in a university population. Dis Nerv Syst1975; 36: 516–7PubMedGoogle Scholar
  26. 26.
    Wentzel JN, Reich T, McClure JM, et al. Premenstrual affective syndrome and affective disorder. Br J Psychiatry 1975; 127: 219–21CrossRefGoogle Scholar
  27. 27.
    Harrison WM, Endicott J, Nee J, et al. Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics 1989; 30(4): 405–11PubMedCrossRefGoogle Scholar
  28. 28.
    Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axisI and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129–34PubMedCrossRefGoogle Scholar
  29. 29.
    Ling FW, Brown CS. Clinical phenomenology of PMS: implications for the physician in a nonpsychiatric specialty area. Proceedings of the Fourth National Institute of Mental Health International Research Conference on the Classification and Treatment of Mental Disorders in General Medical Settings; 1990 Jun; Bethesda (MD)Google Scholar
  30. 30.
    Severino SK, Hurt SW, Shindledecker RD. Late luteal phase dysphoric disorder: spectral analysis of cyclic symptoms. Am J Psychiatry 1989; 146: 1155–60PubMedGoogle Scholar
  31. 31.
    Ernst C, Angst J. The Zurich Study XII. Sex differences in depression. Evidence from longitudinal epidemiological data. Eur Arch Psychiatry Clin Neurosci 1992; 241(4): 222–30Google Scholar
  32. 32.
    Young MA, Scheftner WA, Fawcett J, et al. Gender differences in the clinical features of unipolar major depressive disorder. J Nerv Ment Dis 1990; 178: 200–3PubMedCrossRefGoogle Scholar
  33. 33.
    Frank E, Carpenter LL, Kupfer DJ. Sex differences in recurrent depression: are there any that are significant? Am J Psychiatry 1988; 145: 41–5PubMedGoogle Scholar
  34. 34.
    Casper RC, Belanoff J, Offer D. Gender differences, but no racial group differences, in self-reported psychiatric symptoms in adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 500–8PubMedCrossRefGoogle Scholar
  35. 35.
    Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 421–31PubMedCrossRefGoogle Scholar
  36. 36.
    Rawson NSB, D’Arcy C. Sedative hypnotic drug use in Canada. Health Rep 1991; 3: 33–57PubMedGoogle Scholar
  37. 37.
    Skegg DCG, Doll R, Perry J. Use of medicines in general practice. BMJ 1977; 1: 1561–3PubMedCrossRefGoogle Scholar
  38. 38.
    Halbreich U. Psychiatric disorders in women. In: Weller M, van Kammen D, editors. Progress in clinical psychiatry. London: Saunders, 1997: 96–115Google Scholar
  39. 39.
    Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. Can Med Assoc J 1994; 150: 1801–9Google Scholar
  40. 40.
    Jensvold MF, Hamilton JA. Sex and gender effects in psycho-pharmacology: contributory factors and implications for pharmacotherapy. In: Halbreich U, editor. Psychiatric issues in women. London: Baillière Tindall, 1996: 647–65Google Scholar
  41. 41.
    Jensvold ME. Nonpregnant reproductive-age women. Pt I. The menstrual cycle and psychopharmacology. In: Jensvold MF, Halbreich UH, Hamilton JA, editors. Psychopharmacology and women. Washington, DC: American Psychiatric Press Inc., 1996: 139–69Google Scholar
  42. 42.
    Yonkers KA, Kando JC, Hamilton JA, et al. Gender differences in treatment of depression and anxiety. In: Halbreich U, Montgomery SA, editors. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 59–74Google Scholar
  43. 43.
    Seeman MV. Mental illness in women. In: Goldman MB, Hatch MC, editors. Women and health. San Diego (CA): Academic Press, 2000: 989–96CrossRefGoogle Scholar
  44. 44.
    Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281(13): 1197–202PubMedCrossRefGoogle Scholar
  45. 45.
    Hamilton JA, Yonkers KA. Sex differences in pharmacokinetics of psychotropic medications. Pt II. Effects on selected psychotropics. In: Jensvold M, Halbreich U, Hamilton JA, editors. Psychopharmacology of women: sex, gender, and hormonal considerations. Washington, DC: American Psychiatric Press Inc., 1996: 43–71Google Scholar
  46. 46.
    McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991; 12(4): 141–7PubMedCrossRefGoogle Scholar
  47. 47.
    Halbreich U. Gonadal hormones, reproductive age, and women with depression. Arch Gen Psychiatry 2000; 57(12): 1163–4PubMedCrossRefGoogle Scholar
  48. 48.
    Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44(9): 839–50PubMedCrossRefGoogle Scholar
  49. 49.
    Rubinow DR, Schmidt PJ, Roca CA. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol Bull 1998; 34(3): 289–90PubMedGoogle Scholar
  50. 50.
    Yonkers KA. Assessing unipolar mood disorders in women. Psychopharmacol Bull 1998; 34(3): 261–6PubMedGoogle Scholar
  51. 51.
    Abramowitz ES, Baker AH, Fleiscler S. Onset of depressive psychiatric crisis and the menstrual cycle. Am J Psychiatry 1982; 139: 475–8PubMedGoogle Scholar
  52. 52.
    Bäckström T, Landgren S, Zetterland B. Effects of ovarian steroid hormones on brain excitability and their relation to epilepsy seizure, variation during the menstrual cycle. In: Porter RJ, Mattson RH, Ward AAJ, editors. Advances in epileptology. New York: Raven Press, 1984: 269–77Google Scholar
  53. 53.
    Brockington IF, Margison FR, Schofield EM, et al. The clinical picture of the depressed form of puerperal psychosis. J Affect Disord 1988; 15: 29–37PubMedCrossRefGoogle Scholar
  54. 54.
    Brockington IF, Kelly A, Hall P. Premenstrual relapse puerperal psychosis. J Affect Disord 1988; 14: 287–92PubMedCrossRefGoogle Scholar
  55. 55.
    Endicott J, Halbreich U. Clinical significance of premenstrual dysphoric changes. J Clin Psychiatry 1988; 49(12): 486–9PubMedGoogle Scholar
  56. 56.
    Friedman RC, Hurt SW, Charkin J. Sexual histories and premenstrual affective syndrome in psychiatric inpatients. Am J Psychiatry 1982; 139: 1484–6PubMedGoogle Scholar
  57. 57.
    Gladis MM, Walsh BT. Premenstrual exacerbation of binge eating in bulimia. Psychiatry 1987; 144: 1592–5Google Scholar
  58. 58.
    Hatotani N, Nishikubo M, Iitayama I. Periodic psychosis in the female and the reproductive process. In: Zichella L, Pancheri P, editors. Psychoneuroendocrinology in reproduction. New York: Elsevier North Holland, 1979: 55–68Google Scholar
  59. 59.
    d’Orban PT, Dalton J. Violent crime and the menstrual cycle. Psychol Med 1980; 10: 353–9PubMedCrossRefGoogle Scholar
  60. 60.
    Luggin R, Bernsted L, Petersson B, et al. Acute psychiatric admission related to the menstrual cycle. Acta Psychiatr Scand 1984; 69(6): 461–5PubMedCrossRefGoogle Scholar
  61. 61.
    Price RA, Kidd KK, Weissman MM. Early onset (under age 30 years) and panic disorder as markers etiologic homogeneity in major depression. Arch Gen Psychiatry 1987; 44: 434–40PubMedCrossRefGoogle Scholar
  62. 62.
    Leibenluft E, Ashman SB, Feldman-Naim S, et al. Lack of relationship between menstrual cycle phase and mood in a sample of women with rapid cycling bipolar disorder. Biol Psychiatry 1999; 46(4): 577–80PubMedCrossRefGoogle Scholar
  63. 63.
    Halbreich U, Rojansky N, Palter S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995; 37(7): 434–41PubMedCrossRefGoogle Scholar
  64. 64.
    McEwen BS, Alves SE, Bulloch K. Ovarian steroids and the brain:implications for cognition and aging. Neurology 1997; 48Suppl. 7:S8–15PubMedCrossRefGoogle Scholar
  65. 65.
    Matsumoto A, Arai Y, Osanai M. Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats. Neurosci Res 1985; 2(5): 412–8PubMedCrossRefGoogle Scholar
  66. 66.
    Dickinson SL, Curzon G. 5-Hydroxytryptamine-mediated behaviorin male and female rats. Neuropharmacology 1986; 25: 771–6PubMedCrossRefGoogle Scholar
  67. 67.
    Chakravorty SG, Halbreich U. The influence of estrogen onmonoamine oxidase activity. Psychopharmacol Bull 1997; 33(2): 229–33PubMedGoogle Scholar
  68. 68.
    McEwen BS, Alves SE, Bulloch K, et al. Clinically-relevantbasic sciences studies of gender differences and sex hormones effects. Psychopharmacol Bull 1998; 34: 251–9PubMedGoogle Scholar
  69. 69.
    Wolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992; 12: 2549–54Google Scholar
  70. 70.
    Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89: 484–90PubMedCrossRefGoogle Scholar
  71. 71.
    Halbreich U, Lumley LA. The multiple interactional biological processes that might lead to depression and gender differences in its appearance. J Affect Disord 1993; 29(2-3): 159–73PubMedCrossRefGoogle Scholar
  72. 72.
    McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994; 29: 431–6PubMedCrossRefGoogle Scholar
  73. 73.
    Singh M, Meyer EM, Simpkins JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in Sprague-Dawley rats. Brain Res 1994; 644: 305–12PubMedCrossRefGoogle Scholar
  74. 74.
    Singh M, Meyer EM, Simpkins JW. The effect of ovariectomyand oestradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995; 136: 2320–4PubMedCrossRefGoogle Scholar
  75. 75.
    Simpkins JW, Singh M, Bishop J. The potential role for estrogenreplacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer’s disease. Neurobiol Aging 1994; 15Suppl. 2: S195–7PubMedCrossRefGoogle Scholar
  76. 76.
    Ohkura T, Teshima Y, Isse K. Estrogen increases cerebral and cerebellar blood flow in postmenopausal women. Menopause 1994; 2: 13–8Google Scholar
  77. 77.
    Birge S. The role of estrogen in the treatment of Alzheimer’s disease. Neurology 1997; 48Suppl. 7: S36–41PubMedCrossRefGoogle Scholar
  78. 78.
    Garlow SJ, Musselman DJ, Nemeroff CB. The neurochemistryof mood disorders: clinical studies. In: Charney DS, Nestler EJ, Bunney BS, editors. Neurobiology of mental illness. NewYork: Oxford University Press, 1999: 348–64Google Scholar
  79. 79.
    Young EA, Midgley AR, Carlson NE, et al. Alteration in thehypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiatry 2000; 57(12): 1157–62PubMedCrossRefGoogle Scholar
  80. 80.
    Young E, Korszun A. Psychoneuroendocrinology of depression.Hypothalamic-pituitary-gonadal axis. Psychiatr Clin North Am 1998; 21(2): 309–23PubMedCrossRefGoogle Scholar
  81. 81.
    Archer JS. Relationship between estrogen, serotonin, and depression.Menopause 1999; 6(1): 71–8PubMedCrossRefGoogle Scholar
  82. 82.
    Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 1999; 84(2): 606–10PubMedCrossRefGoogle Scholar
  83. 83.
    Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998; 129(3): 229–40PubMedGoogle Scholar
  84. 84.
    Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology 1999; 146(1): 108–10PubMedCrossRefGoogle Scholar
  85. 85.
    Yonkers KA, Bradshaw KD, Halbreich U. Oestrogens, progestins and mood. In: Steiner M, Yonkers KA, Eriksson E, editors. Mood disorders in women. London: Martin Dunitz Ltd., 2000: 207–32Google Scholar
  86. 86.
    Facts and Comparisons Publishing Group. Estrogens. In: Burnham TH, Schweain SL, Short RM, editors. Drug facts and comparisons 2000. 54th ed. St Louis (MO): Wolters Kluwer, 2000: 217–24Google Scholar
  87. 87.
    Lyman GW, Johnson RN. Assay for conjugated estrogens in tablets using fused-silica capillary gas chromatography. J Chromatogr 1982; 234(1): 234–9PubMedCrossRefGoogle Scholar
  88. 88.
    Delmas PD, Pornel B, Felsenberg D, et al. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group. Bone 1999; 24(5): 517–23Google Scholar
  89. 89.
    Scott RT, Ross B, Anderson C, et al. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991; 77(5): 758–64PubMedGoogle Scholar
  90. 90.
    Muller P, Botta L, Ezzet F. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system. Eur J Clin Pharmacol 1996; 51(3–4): 327–30PubMedGoogle Scholar
  91. 91.
    Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuoussequential transdermal estradiol and norethindrone acetate inrelieving vasomotor symptoms associated with menopause.Am J Obstet Gynecol 2000; 182(1 Pt 1): 7–12PubMedCrossRefGoogle Scholar
  92. 92.
    Ramachandran C, Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev 2000; 42(3): 197–223PubMedCrossRefGoogle Scholar
  93. 93.
    Ellerington MC, Whitcroft SI, Whitehead MI. HRT: developments in therapy. Br Med Bull 1992; 48(2): 401–25PubMedGoogle Scholar
  94. 94.
    Nash HA, Alvarez-Sanchez F, Mishell Jr DR, et al. Estradiol-delivering vaginal rings for hormone replacement therapy. AmJ Obstet Gynecol 1999; 181(6): 1400–6CrossRefGoogle Scholar
  95. 95.
    Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996; 347(9006): 930–3PubMedCrossRefGoogle Scholar
  96. 96.
    Smith RN, Studd JW, Zamblera D, et al. Arandomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102(6): 475–84PubMedCrossRefGoogle Scholar
  97. 97.
    Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183(2): 414–20PubMedCrossRefGoogle Scholar
  98. 98.
    Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiatry 2001; 58(6): 529–34PubMedCrossRefGoogle Scholar
  99. 99.
    Palter S, Halbreich U. Transdermal estradiol treatment improves dysphoric premenstrual syndromes [abstract no. 439]. 146th Annual Meeting Society of Biological Psychiatry; 1993 May 22–27; San Francisco. Biol Psychiatry 1993; 33: 157AGoogle Scholar
  100. 100.
    Halbreich U. Hormonal interventions as antidepressants or adjunct therapy: treatment implications. In: Halbreich U, Montgomery SA, editors. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 273–83Google Scholar
  101. 101.
    De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62(3): 536–41PubMedCrossRefGoogle Scholar
  102. 102.
    Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314(25): 615–20CrossRefGoogle Scholar
  103. 103.
    Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994; 35(11): 2083–93PubMedGoogle Scholar
  104. 104.
    Brayshaw ND, Brayshaw DD. Thyroid hypofunction in premenstrual syndrome. N Engl J Med 1986; 315: 1486PubMedCrossRefGoogle Scholar
  105. 105.
    Roy-Byrne PP, Rubinow DR, Hoban MC, et al. TSH and prolactin responses to TRH in patients with premenstrual syndrome. Am J Psychiatry 1987; 144(4): 480–4PubMedGoogle Scholar
  106. 106.
    Casper RF, Patel-Christopher A, Powell A. Thyrotropin and rolactin responses to thyrotropin-releasing hormone in premenstrual syndrome. J Clin Endocrinol Metab 1989; 68: 608–12PubMedCrossRefGoogle Scholar
  107. 107.
    Halbreich U, Carson S, Rojansky N, et al. 20% of women who reported premenstrual dysphoric changes might have subclinical hypothyroidism [abstract]. 31st Annual Meeting of the American College of Neuropsychopharmacology; 1988; San Juan, Puerto RicoGoogle Scholar
  108. 108.
    Halbreich U, Tworek H. Altered serotonergic activity in womenwith dysphoric premenstrual syndromes. Int J Psychiatry Med 1993; 23(1): 1–27PubMedCrossRefGoogle Scholar
  109. 109.
    Lepage P, Steiner M. Gender and serotonergic dysregulation: implications for late luteal phase dysphoric disorder. In: Cassano GB, Akiskal HS, editors. Serotonin related psychiatric syndromes: clinical and therapeutic links. London: Royal Society of Medicine Service, Congress Symposium Series No 165, 1991Google Scholar
  110. 110.
    Halbreich U, Piletz JE, Carson S, et al. Increased imidazoline and alpha 2 adrenergic binding in platelets of women with dysphoric premenstrual syndromes. Biol Psychiatry 1993; 34(10): 676–86PubMedCrossRefGoogle Scholar
  111. 111.
    Gurguis GN, Yonkers KA, Phan SP, et al. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry 1998; 44(7): 600–9Google Scholar
  112. 112.
    Gurguis GN, Yonkers KA, Blakeley JE, et al. Adrenergic receptorsin premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrualcycle and prediction of luteal phase symptom severity. PsychiatryRes 1998; 79(1): 31–42PubMedCrossRefGoogle Scholar
  113. 113.
    Halbreich U, Kas D. Variations in the Taylor MAS of womenwith pre-menstrual syndrome. J Psychosom Res 1977; 21(5):391–3PubMedCrossRefGoogle Scholar
  114. 114.
    Sandberg D, Endicott J, Harrison W, et al. Sodium lactate infusion in late luteal phase dysphoric disorder. Psychiatry Res 1993; 46: 79–88PubMedCrossRefGoogle Scholar
  115. 115.
    LeMeledo JM, Bradwein J, Koszycki D, et al. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry 1995; 52: 605–6CrossRefGoogle Scholar
  116. 116.
    Halbreich U. Menstrually related disorders — towards interdisciplinary international diagnostic criteria. Cephalalgia 1997; 17 Suppl. 20: 1–4Google Scholar
  117. 117.
    Kornstein SG, McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J Clin Psychiatry 2000; 61 Suppl. 11: 18–27Google Scholar
  118. 118.
    Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157(9): 1445–52PubMedCrossRefGoogle Scholar
  119. 119.
    Steiner M, Wheadon D, Kreider M, et al. Antidepressant response to paroxetine by gender [abstract no. 462]. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22–27; San FranciscoGoogle Scholar
  120. 120.
    Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149(5): 587–95PubMedGoogle Scholar
  121. 121.
    Yonkers KA, Zlotnick C, Allsworth J, et al. Is the course of panic disorder the same in women and men? Am J Psychiatry 1998; 155(5): 596–602PubMedGoogle Scholar
  122. 122.
    Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979; 36: 550–4PubMedCrossRefGoogle Scholar
  123. 123.
    Michael C, Kantor H, Shore H. Further psychometric evaluation of older women — the effect of estrogen administration. J Gerontol 1970; 25: 337–4PubMedCrossRefGoogle Scholar
  124. 124.
    Prange AJ. Estrogen may well affect response to antidepressant. JAMA 1972; 219: 143–4CrossRefGoogle Scholar
  125. 125.
    Shapira B, Oppenheim G, Zohar J, et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 1985; 20(5): 576–9PubMedCrossRefGoogle Scholar
  126. 126.
    Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust 1977; 2: 162–3PubMedGoogle Scholar
  127. 127.
    Coope J, Thomson JM, Poller L. Effects of natural oestrogen replacement therapy on menopausal symptoms and blood clotting. BMJ 1975; 4(5989): 139–43PubMedCrossRefGoogle Scholar
  128. 128.
    Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981; 31: 134–40PubMedGoogle Scholar
  129. 129.
    Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997; 5(2): 97–106Google Scholar
  130. 130.
    Schneider LS, Small G, Clary C. Estrogen replacement therapy and antidepressant response to sertraline [abstract]. In: Annual Meeting of the American Psychiatric Association; 1998 May 30–June 4; Toronto (ON); 1998Google Scholar
  131. 131.
    Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999; 55(1): 11–7PubMedCrossRefGoogle Scholar
  132. 132.
    Steiner M, Born L, Marton P. Menarche and mood disorders in adolescence. In: Steiner M, Yonkers K, Eriksson E, editors. Mood disorders in women London: Martin Dunitz, 2000: 247–68Google Scholar
  133. 133.
    Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 1998; 18(7): 765–94PubMedCrossRefGoogle Scholar
  134. 134.
    Martin A, Cohen DJ. Adolescent depression: window of (missed?) opportunity. Am J Psychiatry 2000; 157(10): 1549–51PubMedCrossRefGoogle Scholar
  135. 135.
    Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychol Med 1998; 28(1): 109–26PubMedCrossRefGoogle Scholar
  136. 136.
    Lewinsohn PM, Rohde P, Seeley JR, et al. Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry 2000; 157(10): 1584–91PubMedCrossRefGoogle Scholar
  137. 137.
    Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998; 7: 3–14PubMedCrossRefGoogle Scholar
  138. 138.
    Angold A, Costello EJ, Worthman CM. Puberty and depression: the roles of age, pubertal status and pubertal timing. Psychol Med 1998; 28(1): 51–61PubMedCrossRefGoogle Scholar
  139. 139.
    Angold A, Costello EJ, Erkanli A, et al. Pubertal changes in hormone levels and depression in girls. Psychol Med 1999; 29(5): 1043–53PubMedCrossRefGoogle Scholar
  140. 140.
    Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147(12): 1634–6PubMedGoogle Scholar
  141. 141.
    Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982; 72(11): 1257–64PubMedCrossRefGoogle Scholar
  142. 142.
    Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol 1987; 30(2): 367–76PubMedCrossRefGoogle Scholar
  143. 143.
    Merikangas KR, Foeldenyl M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243: 23–32PubMedCrossRefGoogle Scholar
  144. 144.
    Ramcharan S, Love EJ, Fick GH, et al. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992; 45(4): 377–92PubMedCrossRefGoogle Scholar
  145. 145.
    Hurt SW, Schnurr PP, Severino SK, et al. Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints. Am J Psychiatry 1992; 149(4): 525–30PubMedGoogle Scholar
  146. 146.
    Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999; 8(5): 663–79PubMedCrossRefGoogle Scholar
  147. 147.
    Frank R. The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 1931; 26: 1053–7CrossRefGoogle Scholar
  148. 148.
    Dalton K. The premenstrual syndrome. London: Heinemann, 1964Google Scholar
  149. 149.
    Halbreich U, Endicott J, Goldstein S, et al. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986; 74(6): 576–86PubMedCrossRefGoogle Scholar
  150. 150.
    Freeman EW, Sondheimer SJ, Rickels K, et al. PMS treatment approaches and progesterone therapy. Psychosomatics 1985; 26(10): 811–6PubMedCrossRefGoogle Scholar
  151. 151.
    Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome: a placebo-controlled, randomized, double-blind study. JAMA 1990; 264: 349–53PubMedCrossRefGoogle Scholar
  152. 152.
    Halbreich U, Alt IH, Paul L. Premenstrual changes: impaired hormonal homeostasis. Neurol Clin 1988; 6(1): 173–94PubMedGoogle Scholar
  153. 153.
    Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338(4): 209–16PubMedCrossRefGoogle Scholar
  154. 154.
    Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56(6): 1066–9PubMedGoogle Scholar
  155. 155.
    Halbreich U. Menstrually related disorders: what we do know, what we only believe that we know, and what we know that we do not know. Crit Rev Neurobiol 1995; 9(2–3): 163–75PubMedGoogle Scholar
  156. 156.
    Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332(23): 1529–34Google Scholar
  157. 157.
    Yonkers KA, Halbreich U, Freeman E, et al. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996; 32(1): 41–6PubMedGoogle Scholar
  158. 158.
    Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry 1990; 47(3): 270–5PubMedCrossRefGoogle Scholar
  159. 159.
    Halbreich U, Smoller JW Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58(9): 399–402PubMedCrossRefGoogle Scholar
  160. 160.
    Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997; 278(12): 983–8PubMedCrossRefGoogle Scholar
  161. 161.
    Muse KN, Futterman LA, Yen SSC. The premenstrual syndrome: effects of medical oophrectomy. N Engl J Med 1984; 311: 1345–9PubMedCrossRefGoogle Scholar
  162. 162.
    Magos AL, Brincat M, Studd JWW Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical oral norethisterone: placebo controlled study. BMJ 1986; 292: 1629–33PubMedCrossRefGoogle Scholar
  163. 163.
    Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; II(8665): 730–2CrossRefGoogle Scholar
  164. 164.
    Dahr V, Murphy BEP. Double-blind randomized crossover trial of luteal phase estrogens (Premarin®). Psychoneuroendocrinology 1990; 15(5): 489–93CrossRefGoogle Scholar
  165. 165.
    Halbreich U. RU-486, estrogen and leuprolide as treatment for PMS [abstract]. In: 30th Annual Meeting of the International Society of Psychoneuroendocrinology; 1999 Jul 30–Aug 3; Orlando (FL)Google Scholar
  166. 166.
    Cooper PJ, Murray L, Hooper R, et al. The development and validation of a predictive index for postpartum depression. Psychol Med 1996; 26(3): 627–34PubMedCrossRefGoogle Scholar
  167. 167.
    Troutman BR, Cutrona CE. Nonpsychotic postpartum depression among adolescent mothers. J Abnorm Psychol 1990; 99(1): 69–78PubMedCrossRefGoogle Scholar
  168. 168.
    O’Hara MW, Zekoski EM, Philipps LH, et al. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 1990; 99(1): 3–15PubMedCrossRefGoogle Scholar
  169. 169.
    Reighard FT, Evans ML. Use of the Edinburgh Postnatal Depression Scale in a southern, rural population in the United States. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1219–24PubMedCrossRefGoogle Scholar
  170. 170.
    Roy A, Gang P, Cole K, et al. Use of Edinburgh Postnatal Depression Scale in a North American population. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 501–4PubMedCrossRefGoogle Scholar
  171. 171.
    Whiffen VE. Vulnerability of postpartum depression: a prospective multivariate study. J Abnorm Psychol 1988; 97: 467–74PubMedCrossRefGoogle Scholar
  172. 172.
    Demyttenaere K, Lenaerts H, Nijs P, et al. Individual coping style and psychological attitudes during pregnancy predict depression levels during pregnancy and during postpartum. Acta Psychiatr Scand 1995; 91: 95–102PubMedCrossRefGoogle Scholar
  173. 173.
    Terry DJ, Mayocchi L, Hynes GJ. Depressive symptomatology in new mothers: a stress and coping perspective. J Abnorm Psychol 1996; 105(2): 220–31PubMedCrossRefGoogle Scholar
  174. 174.
    Cox JL, Connor Y, Kendell RE. Prospective study of the psychiatric disorders of childbirth. Br J Psychiatry 1982; 140: 111–7PubMedCrossRefGoogle Scholar
  175. 175.
    Whiffen VE. Is postpartum depression a distinct diagnosis? Clin Psychol Rev 1992; 12: 485–508CrossRefGoogle Scholar
  176. 176.
    Carothers AD, Murray L. Estimating psychiatric morbidity by logistic regression: application to post-natal depression in a community sample. Psychol Med 1990; 20(3): 695–702PubMedCrossRefGoogle Scholar
  177. 177.
    Zelkowitz P, Milet TH. Screening for post-partum depression in a community sample. Can J Psychiatry 1995; 40(2): 80–6PubMedGoogle Scholar
  178. 178.
    Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000; 157(6): 924–30PubMedCrossRefGoogle Scholar
  179. 179.
    Krapelin E. Lehrbuch der psychiatre. New York: MacMillan, 1907Google Scholar
  180. 180.
    Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977; 34: 98-111PubMedCrossRefGoogle Scholar
  181. 181.
    Weissman MM. The myth of involutional melancholia. JAMA 1979; 242(8): 742–4PubMedCrossRefGoogle Scholar
  182. 182.
    Schmidt PJ, Roca CA, Bloch M, et al. The perimenopause and affective disorders. Semin Reprod Endocrinol 1997; 15(1): 91–100PubMedCrossRefGoogle Scholar
  183. 183.
    Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29(2–3): 85–96PubMedCrossRefGoogle Scholar
  184. 184.
    Weissman MM, Leaf PJ, Bruce ML, et al. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry 1988; 145(7): 815–9PubMedGoogle Scholar
  185. 185.
    Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18(1): 141–53PubMedCrossRefGoogle Scholar
  186. 186.
    Angst J, Frey R, Lohmeyer R, et al. Bipolar manic depressive psychoses: results of a genetic investigation. Hum Genet 1980; 55: 237–54PubMedCrossRefGoogle Scholar
  187. 187.
    Aylward M, Holly F, Parker RI. An evaluation of clinical response to piperazine oestrone sulphate (‘Harmogen’) in menopausal patients. Curr Med Res Opin 1974; 2(7): 417PubMedCrossRefGoogle Scholar
  188. 188.
    Montgomery JC, Appleby L, Brincat M, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987; I(8528): 297–9CrossRefGoogle Scholar
  189. 189.
    Strickler RC, Borth R, Cecutti A, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med 1977; 7: 631–9PubMedCrossRefGoogle Scholar
  190. 190.
    Coope I. The menopause: is oestrogen therapy affective in the treatment of postmenopausal depression? J R C Gen Pract 1981; 31: 134–40Google Scholar
  191. 191.
    Thompson J, Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. BMJ 1977 Nov 19; 2(6098): 1317–9CrossRefGoogle Scholar
  192. 192.
    Kouri E, Halbreich U. Psychotrophic effects of hormonal replacement therapy. Drugs Today 1998; 34(3): 251–7PubMedCrossRefGoogle Scholar
  193. 193.
    Ditkoff EC, Crary WG, Cristo M, et al. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78: 991–5PubMedGoogle Scholar
  194. 194.
    Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psycho-neuroendocrinology 1985; 10(3): 325–35CrossRefGoogle Scholar
  195. 195.
    Coppen A, Bishop M, Beard RJ. Effects on piperazine oestrone sulphate on plasma tryptophan, oestrogens, gonadotrophins and psychological functioning in women following hysterectomy. Curr Med Res Opin 1977; 4: 29–36CrossRefGoogle Scholar
  196. 196.
    George GCW, Utian WH, Beumont PJV, et al. Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J 1973; 47: 2387–8PubMedGoogle Scholar
  197. 197.
    Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47(4): 339–51PubMedGoogle Scholar
  198. 198.
    Brincat M, Magos A, Studd JW, et al. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Lancet 1984; I(8367): 16–8CrossRefGoogle Scholar
  199. 199.
    Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy — a placebo-controlled study. Int J Fertil Menopausal Stud 1995; 40(2): 73–8PubMedGoogle Scholar
  200. 200.
    Fedor-Freybergh. The influence on oestrogen on wellbeing and mental performance in climacteric postmenopausal women. Acta Obstet Gynecol Scand 1977; 64: 2–10CrossRefGoogle Scholar
  201. 201.
    Furuhjelm M, Karlgren E, Carlstrom K. The effect of estrogen therapy on somatic and psychical symptoms in postmenopausal women. Acta Obstet Gynecol Scand 1984; 63(7): 655–61PubMedCrossRefGoogle Scholar
  202. 202.
    Wiklund I, Karlberg J, Mattson L. Quality of life menopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168: 824–30PubMedGoogle Scholar
  203. 203.
    Paterson MEL. A randomized double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters. Maturitas 1982; 4: 83–94PubMedCrossRefGoogle Scholar
  204. 204.
    Saletu B, Brandstatter N, Metkam M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology (Berl) 1995; 122: 321–9CrossRefGoogle Scholar
  205. 205.
    Campbell S. Double blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell S, editor. The management of menopause and postmenopausal years. Lancaster: MTP, 1976: 149–58CrossRefGoogle Scholar
  206. 206.
    Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4(1): 31–47PubMedGoogle Scholar
  207. 207.
    Gerdes LC, Sonnendecker EWW, Polakow ES. Psychological changes effected by estrogen-progestogen and clonidine treatment in climacteric women. Am J Obstet Gynecol 1982; 142(1): 98–104PubMedGoogle Scholar
  208. 208.
    Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet 1999; 65(1): 35–8Google Scholar
  209. 209.
    Maoz B, Durst N. The effects of oestrogen therapy on the sex life of post-menopausal women. Maturitas 1980; 2(4): 327–36PubMedCrossRefGoogle Scholar
  210. 210.
    Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992; 80: 30–6PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.BioBehavioral ProgramState University of New York at BuffaloBuffaloUSA

Personalised recommendations